About the Authors
- Catherine Féart
-
* E-mail: catherine.feart@isped.u-bordeaux2.fr
Affiliations INSERM, U897, Bordeaux, France, Université Bordeaux Segalen, Bordeaux, France
- Catherine Helmer
-
Affiliations INSERM, U897, Bordeaux, France, Université Bordeaux Segalen, Bordeaux, France
- Hervé Fleury
-
Affiliation Université Bordeaux Segalen, Bordeaux, France
- Yannick Béjot
-
Affiliation Department of Neurology, University Hospital of Dijon, Dijon Stroke Registry, EA4184, Faculty of Medicine of Dijon, University of Burgundy, Dijon, France
- Karen Ritchie
-
Affiliations INSERM, U888, Montpellier, France, Faculty of Medicine, Imperial College London, London, United Kingdom
- Philippe Amouyel
-
Affiliations INSERM, UMR744, Lille, France, Institut Pasteur de Lille, University of Lille 2, Lille, France
- Susanna Schraen-Maschke
-
Affiliations Institut Pasteur de Lille, University of Lille 2, Lille, France, INSERM, U837, Lille, France
- Luc Buée
-
Affiliations Institut Pasteur de Lille, University of Lille 2, Lille, France, INSERM, U837, Lille, France
- Jean-Charles Lambert
-
Affiliations INSERM, UMR744, Lille, France, Institut Pasteur de Lille, University of Lille 2, Lille, France
- Luc Letenneur
-
Affiliations INSERM, U897, Bordeaux, France, Université Bordeaux Segalen, Bordeaux, France
- Jean-François Dartigues
-
Affiliations INSERM, U897, Bordeaux, France, Université Bordeaux Segalen, Bordeaux, France
Competing Interests
Sanofi-Aventis has an interest in anti-Amyloid Beta antibody therapy for treating Alzheimer's disease; specifically, an anti-Amyloid Beta antibody therapy is in development. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: CF CH LL JFD. Performed the experiments: CF CH LL JFD. Analyzed the data: CF CH LL JFD JCL KR HF YB PA SSM LB. Contributed reagents/materials/analysis tools: SSM LB JCL PA HF YB. Wrote the paper: CF CH LL JFD. Provided significant advice: HF YB KR PA SSM LB JCL.